Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK announces results of phase III Tykerb trial

GSK announces results of phase III Tykerb trial

19th May 2008

GlaxoSmithKline (GSK) has announced the results of a phase III clinical trial evaluating Tykerb/Tyverb (lapatnib) plus Herceptin (trastuzumab) as a treatment for cancer.

Results of the study showed that a using both drugs together in patients with HER2-positive metastatic breast cancer resulted in a clinically meaningful extension of progression-free survival.

The firm reports that the combination of Tykerb and Herceptin to attack the HER2 (ErB2) receptor both internally and externally could result in the creation of a more complete HER2 blockade.

Furthermore, the trial results showed activity of Tykerb when used alone despite previous treatment with multiple lines of Herceptin and chemotherapy.

Joyce O’Shaughnessy, of the Baylor-Sammons Cancer Centre from Texas Oncology, said: “Many women with HER2 positive breast cancer are still very active and living full lives, yet when their disease progresses after trastuzumab and chemotherapy, we have had limited treatment options.”

She added that the attack on HER2 from multiple angles an exciting and novel approach showing the progress being made in treating this complex type of breast cancer.

Last week, GSK announced the global testing of Tykerb in the early stages of the disease via a partnership with the Breast International Group.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.